Navigation Links
Patient Advocate Foundation Announces Additional Support for Patient Co-Pay Relief Program Serving Nonsquamous Non-Small Cell Lung Cancer (NSCLC) Patients

HAMPTON, Va., June 3, 2011/PRNewswire-USNewswire/ -- Patient Advocate Foundation (PAF) is pleased to announce that it has received a new contribution enabling it to begin offering support to patients suffering with nonsquamous non-small cell lung cancer (NSCLC) through its Co-Pay Relief Program (CPR) on June 6, 2011 at 11:00 AM EDT. PAF is a national non-profit organization that seeks to safeguard patients through effective mediation assuring access to care, maintenance of employment and preservation of their financial stability relative to their diagnosis of life threatening or debilitating diseases.

PAF's Co-Pay Relief Program provides direct financial support for pharmaceutical co-payments to insured patients, including Medicare Part D beneficiaries, who financially and medically qualify.  Since the program's inception in April 2004, CPR distributed more than $120 million in assistance to more than 46,000 patients who were unable to afford their pharmaceutical co-payments.

"A debilitating or life-threatening diagnosis can be the most overwhelming experience a person may ever face in his or her lifetime. Coupled with high-cost pharmaceutical co-pay expenses, the journey can become significantly more challenging to manage," said Nancy Davenport-Ennis, Founder and CEO of PAF. "Patient Advocate Foundation created the Co-Pay Relief Program in 2004 after receiving an increased number of patients seeking co-pay assistance for pharmaceutical drugs, so we are particularly pleased to be able to offer assistance to more patients every year."

Globally, lung cancer is the most common form of cancer and the biggest killer, causing 1.3 million cancer deaths annually.  About 85 – 90 percent of all lung cancers are NSCLC. The liver, bones and brain are potential targets if the cancerous cells enter the bloodstream. NSCLC comprises a group of histologies or tumor types differentiated by cellular structure. Nonsquamous histology includes adenocarcinoma and large cell carcinoma, which account for more than half of all NSCLC diagnoses, as well histologies classified as "other."

In 2010, Co-Pay Relief Program assisted 13,848 patients, a 49.59 percent increase from 2009, and allocated approximately $31.2 million to patients to help alleviate the financial burden of out-of-pocket pharmaceutical co-payments.  Nearly half of CPR patients were over the age of 65, a 10.09 percent increase from 2009, which indicates that seniors are facing financial obstacles due to both medical and cost-of-living debt crises. Additionally, 16 percent of CPR patients are age 46 to 55 years and six percent are 36 to 45 years of age.

Patient Advocate Foundation and its companion organization, the National Patient Advocate Foundation (NPAF), were founded on the principle that health care is a basic human need and shared social responsibility.  Annually, PAF receives thousands of contacts requesting information and assistance via their toll-free hotline, as well as online, with complete direct, sustained case management services provided to patients from all fifty states free of charge.  For more information about PAF, visit or call toll free (800) 532-5274. For more information about PAF's Co-Pay Relief Program visit or call toll free (866) 512-3861.

SOURCE Patient Advocate Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
Breaking Medicine News(10 mins):